eltrombopag olamine tablets price

Description:

Elbonix is an orally bioavailable, small-molecule TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor and initiates signaling cascades that induce proliferation and differentiation from bone marrow progenitor cells.Elbonix is available in tablet form for oral administration.
Medicine Information Source: BeaconPharma
 

Elbonix 25mg/50mg
(Eltrombopag Olamine)

Eltrombopag Olamine Tablets
Price (28 tablets)

$175/$262

Elbonix 25 tablet : Each film coated tablet contains Eltrombopag Olamine INN equivalent to Eltrombopag 25 mg.
Elbonix 50 tablet : Each film coated tablet contains Eltrombopag Olamine INN equivalent to Eltrombopag 50 mg.

Elbonix is an orally bioavailable, small-molecule TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor and initiates signaling cascades that induce proliferation and differentiation from bone marrow progenitor cells.Elbonix is available in tablet form for oral administration.

Eltrombopag is an orally bioavailable, small-molecule TPO-receptor agonist that interacts with
the transmembrane domain of the human TPO-receptor and initiates signaling cascades that
induce proliferation and differentiation from bone marrow progenitor cells.

Recommended Dosage
Chronic Immune (Idiopathic) Thrombocytopenia
Use the lowest dose of Eltrombopag to achieve and maintain a platelet count greater than or
equal to 50 x 109/L as necessary to reduce the risk for bleeding. Dose adjustments are based
upon the platelet count response. Do not use Eltrombopag to normalize platelet counts. In
clinical trials, platelet counts generally increased within 1 to 2 weeks after starting Eltrombopag
and decreased within 1 to 2 weeks after discontinuing Eltrombopag.
Initial Dose Regimen: Adult and Pediatric Patients 6 Years and Older with ITP: Initiate
Eltrombopag at a dose of 50 mg once daily, except in patients who are of East Asian ancestry
(such as Chinese, Japanese, Taiwanese or Korean) or who have mild to severe hepatic
impairment (Child-Pugh Class A, B, C). For patients of East Asian ancestry with ITP, initiate
Eltrombopag at a reduced dose of 25 mg once daily. For patients with ITP and mild, moderate or
severe hepatic impairment (Child-Pugh Class A, B, C), initiate Eltrombopag at a reduced dose of
25 mg once daily.
For patients of East Asian ancestry with ITP and hepatic impairment (Child-Pugh Class A, B, C),
consider initiating Eltrombopag at a reduced dose of 12.5 mg once daily.
Pediatric Patients with ITP Aged 1 to 5 Years: Initiate Eltrombopag at a dose of 25 mg once
daily.
Monitoring and Dose Adjustment: After initiating Eltrombopag, adjust the dose to achieve and
maintain a platelet count greater than or equal to 50 x 109/L as necessary to reduce the risk for
bleeding. Do not exceed a dose of 75 mg daily. Monitor clinical hematology and liver tests
regularly throughout therapy with Eltrombopag and modify the dosage regimen of Eltrombopag
based on platelet counts as outlined in Table 1. During therapy with Eltrombopag, assess CBCs
with differentials, including platelet counts, weekly until a stable platelet count has been
achieved. Obtain CBCs with differentials, including platelet counts, monthly thereafter.
When switching between the oral suspension and tablet, assess platelet counts weekly for 2
weeks and then follow standard monthly monitoring.
 
In patients with ITP and hepatic impairment (Child-Pugh Class A, B, C), after initiating
Eltrombopag or after any subsequent dosing increase, wait 3 weeks before increasing the dose.
Modify the dosage regimen of concomitant ITP medications, as medically appropriate, to avoid
excessive increases in platelet counts during therapy with Eltrombopag. Do not administer more
than one dose of Eltrombopag within any 24-hour period.
Discontinuation: Discontinue Eltrombopag if the platelet count does not increase to a level
sufficient to avoid clinically important bleeding after 4 weeks of therapy with Eltrombopag at the
maximum daily dose of 75 mg. Excessive platelet count responses, as outlined in Table 1, or
important liver test abnormalities also necessitate discontinuation of Eltrombopag. Obtain CBCs
with differentials, including platelet counts, weekly for at least 4 weeks following discontinuation
of Eltrombopag.
Chronic Hepatitis C-associated Thrombocytopenia
Use the lowest dose of Eltrombopag to achieve and maintain a platelet count necessary to
initiate and maintain antiviral therapy with Pegylated interferon and Ribavirin. Dose adjustments
are based upon the platelet count response. Do not use Eltrombopag to normalize platelet
counts. In clinical trials, platelet counts generally began to rise within the first week of treatment
with Eltrombopag.
Initial Dose Regimen: Initiate Eltrombopag at a dose of 25 mg once daily.
Monitoring and Dose Adjustment: Adjust the dose of Eltrombopag in 25-mg increments every 2
weeks as necessary to achieve the target platelet count required to initiate antiviral therapy.
Monitor platelet counts every week prior to starting antiviral therapy.
During antiviral therapy, adjust the dose of Eltrombopag to avoid dose reductions of
Peginterferon. Monitor CBCs with differentials, including platelet counts, weekly during antiviral
therapy until a stable platelet count is achieved. Monitor platelet counts monthly thereafter. Do
not exceed a dose of 100 mg daily. Monitor clinical hematology and liver tests regularly
throughout therapy with Eltrombopag.
For specific dosage instructions for Peginterferon or Ribavirin, refer to their respective
prescribing information.
The most common side effects of Eltrombopag in adults when used to treat chronic ITP are: In
adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and
greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting,
increased ALT, myalgia and urinary tract infection.
In pediatric patients age 1 year and older with ITP, the most common adverse reactions (greater
than or equal to 10% and greater than placebo) were upper respiratory tract infection and
nasopharyngitis.
In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse
reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia,
fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia,
insomnia, cough, pruritus, chills, myalgia, alopecia and peripheral edema.
In patients with severe aplastic anemia, the most common adverse reactions (greater than or
equal to 20%) were: nausea, fatigue, cough, diarrhea and headache.

Hepatotoxicity: Monitor liver function before and during therapy.
Thrombotic/Thromboembolic Complications: Portal vein thrombosis has been reported in
patients with chronic liver disease receiving Eltrombopag. Monitor platelet counts regularly.

There is no contraindications for Eltrombopag

Pregnancy Category C. There are no adequate and well-controlled studies of Eltrombopag use
in pregnancy. In animal reproduction and developmental toxicity studies, there was evidence of
embryolethality and reduced fetal weights at maternally toxic doses. Eltrombopag should be
used in pregnancy only if the potential benefit to the mother justifies the potential risk to the
fetus.

Take Eltrombopag at least 2 hours before or 4 hours after any medications or products
containing polyvalent cations such as antacids, calcium-rich foods and mineral supplements

Elbonix 25 Tablet: Each commercial box contains 28 tablets in Alu-Alu blister pack.
Elbonix 50 Tablet: Each commercial box contains 28 tablets in Alu-Alu blister pack.

Buying Eltrombopag Olamine Tablets is always costly. But our Elbonix tablet is an excellent quality medicine with low cost. Beacon Pharmaceuticals Limited manufactures Elbonix tablet and It is one of the renowned Pharmaceuticals company of Bangladesh. If you are interested to buy Eltrombopag Olamine Tablets then contact us.

 

Contact US for Order